This topic contains a solution. Click here to go to the answer

Author Question: Which of the following is atypical of a female juvenile offender? A) 13 to 18 years old B) a ... (Read 16 times)

Kthamas

  • Hero Member
  • *****
  • Posts: 546
Which of the following is atypical of a female juvenile offender?
 
  A) 13 to 18 years old
  B) a history of healthy relationships with her parents, especially her father
  C) from an unstable family background
  D) mental health issues

Question 2

Which of the following statements is the MOST TRUE?
 
  A) The challenge to improving aftercare is much easier today.
  B) Low recidivism rates have inspired experimentation.
  C) The most widely used program provides intensive supervision to low-risk youthful offenders.
  D) Juveniles released from training schools are even less prepared for community living than they were in the past.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

kthug

  • Sr. Member
  • ****
  • Posts: 332
Answer to Question 1

B

Answer to Question 2

D




Kthamas

  • Member
  • Posts: 546
Reply 2 on: Aug 17, 2018
Wow, this really help


JCABRERA33

  • Member
  • Posts: 344
Reply 3 on: Yesterday
Excellent

 

Did you know?

About 100 new prescription or over-the-counter drugs come into the U.S. market every year.

Did you know?

The oldest recorded age was 122. Madame Jeanne Calment was born in France in 1875 and died in 1997. She was a vegetarian and loved olive oil, port wine, and chocolate.

Did you know?

Alzheimer's disease affects only about 10% of people older than 65 years of age. Most forms of decreased mental function and dementia are caused by disuse (letting the mind get lazy).

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library